TB-500, the peptide usually paired with BPC-157. The honest status, here.
Under the same FDA compounding review as BPC-157. We won't pretend it's for sale, we'll tell you exactly where it stands and notify you the moment it's legitimately available.
Prescription required. Reviewed by a named US-licensed clinician, dispensed by a licensed pharmacy, third-party batch-tested.
No charge to see your plan. You only pay if a clinician prescribes.
Batch Tested
Clinicians
Peptide Tracker
20,000+ licensed clinicians · 50-state coverage.
The molecule is easy to find. The safe version isn’t.
Most peptides online ship under a “research use only: not for human consumption” label. That one phrase lets a seller skip FDA oversight, sterility testing, and any real manufacturing standard, and hands the entire risk to you.
- No research-chemical vials.
- No “not for human use” labels.
- No anonymous overseas seller.
- A clinician, a licensed pharmacy, and a test result you can actually see.
Prescribed by a US-licensed clinician. Compounded in a US-licensed 503A/503B pharmacy to USP sterility and potency standards. Third-party tested every batch: identity, potency, and sterility. Monitored as an actual clinical relationship, not a one-time sale.
Compounded medications are not FDA-approved. Where that applies, we say so. Status and timelines are tracked openly on our FDA Tracker.
See exactly where every compound standsYou're here for the recovery answer, and the truth about it.
Where TB-500 actually stands today.
TB-500 is one of seven peptides under FDA review, on the same docket as BPC-157. Nothing has been reclassified. The July 23 meeting is advisory, we're not going to pretend it's for sale. Join the list and we'll tell you the moment it legitimately changes.
Reclassification is not the same as FDA approval.
What TB-500 is, and what we still don't know.
They're different peptides often used together, and both are under the same FDA review. The honest version below; the part most sites skip is the part that matters most.
A synthetic 7-amino-acid fragment related to thymosin beta-4 (Tβ4), discussed for soft-tissue and tendon recovery, almost always alongside BPC-157.
Active-agers and athletes with stubborn tendon and muscle injuries who already know the BPC-157 conversation and want the peptide it's usually paired with.
Evidence grade D: animal-dominant, and the marketed fragment isn't trial-grade Tβ4. WADA-banned (S0). We don't make healing claims it hasn't earned.
The honest answers.
Be first in line, the honest way.
Join the status waitlist. We'll notify you the moment TB-500 is legitimately available, and keep you posted on the FDA review in plain English.
The FDA's advisory committee reviews compounded TB-500, alongside BPC-157, on July 23–24, 2026. Join the list to get the outcome in plain English the day it lands, and your place in line if it clears. (Advisory only; not an approval or a launch date.)